David Y. Graham, MD; Yoshio Yamaoka, MD, PhD
Potential Financial Conflicts of Interest: Dr. Graham has received small amounts of grant support and/or free drugs or urea breath tests from Meretek Diagnostics, Janssen/Eisai, TAP Pharmaceuticals, and Biohit for investigator-initiated and investigator-controlled research in the area of H. pylori infection. He is a paid consultant for Otsuka Pharmaceuticals; a member of the Board of Directors of Meretek Diagnostics, the manufacturer of the 13C-urea breath test; and a consultant to Novartis with regard to H. pylori vaccine development. Finally, he receives royalties on the Baylor College of Medicine patent covering the serologic test HM-CAP (E-Z-EM, Lake Success, New York).
Graham DY, Yamaoka Y. Ethical Considerations of Comparing Sequential and Traditional Anti–Helicobacter pylori Therapy. Ann Intern Med. 2007;147:434–435. doi: https://doi.org/10.7326/0003-4819-147-6-200709180-00022
Download citation file:
Published: Ann Intern Med. 2007;147(6):434-435.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use